Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases.

Autoimmune bullous diseases comprise a group of conditions characterised by the formation of blisters on the skin and mucous membranes due to aberrant immune responses. Central to many of these ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with disease flares experience poorer quality ...

Workup for underlying diseases should be pursued after diagnosis. Common laboratory tests include CBC, renal function tests, LFTs, and UA. 1,4 Other tests based on suspicion of underlying diseases ...

Autoimmune bullous diseases (AMBD) are a group of rare autoimmune disorders that primarily affect the skin and mucous membranes. Our AMBD clinic specializes in the diagnosis and comprehensive ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

Please provide your email address to receive an email when new articles are posted on . Sustained disease remission occurred in 20% of the study cohort vs. 4% of the placebo group at week 36. 41% of ...

Remibrutinib, a BTK inhibitor, offers a new oral treatment for chronic spontaneous urticaria, providing an alternative to traditional therapies. Experts discuss groundbreaking therapies in dermatology ...

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...